COVID-19 Vaccine in Inherited Metabolic Disorders Patients: A Cross-Sectional Study on Rate of Acceptance, Safety Profile and Effect on Disease
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Statistical Analysis
3. Results
3.1. Study Population
3.2. Vaccination Rate
3.3. Adverse Event Rate and Disease Effects
3.4. Type of Adverse Events
3.5. Vaccination Refusals
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
References
- World Health Organization Media Center. Global Alliance for Vaccines and Immunization. 2011. Fact Sheet No. 169. Available online: https://apps.who.int/iris/handle/10665/79077?show=full (accessed on 15 May 2000).
- Fritsche, P.J.; Helbling, A.; Ballmer-Weber, B.K. Vaccine hypersensitivity—Update and overview. Swiss Med. Wkly. 2010, 140, 238–246. [Google Scholar] [PubMed]
- World Health Organisation. WHO Coronavirus (COVID-19) Dashboard. Available online: https://COVID-19.who.int (accessed on 5 March 2022).
- Tatar, M.; Wilson, F.A. The largest vaccination campaign in history: A golden opportunity for bundling public health interventions. J. Glob. Health 2021, 11, 03076. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W.; et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021, 21, 181–192. [Google Scholar] [CrossRef]
- Han, B.; Song, Y.; Li, C.; Yang, W.; Ma, Q.; Jiang, Z.; Li, M.; Lian, X.; Jiao, W.; Wang, L.; et al. Safety, tolerability and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A randomised, double-blind, and placebo-controlled, phase 1/2 clinical trial. Lancet Infect. Dis. 2021, 21, 1645–1653. [Google Scholar] [CrossRef]
- Bueno, S.M.; Abarca, K.; González, P.A.; Gálvez, N.M.; Soto, J.A.; Duarte, L.F.; Schultz, B.M.; Pacheco, G.A.; González, L.A.; Vázquez, Y.; et al. Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. MedRxiv 2021. [Google Scholar] [CrossRef]
- Wu, Q.; Dudley, M.Z.; Chen, X.; Bai, X.; Dong, K.; Zhuang, T.; Salmon, D.; Yu, H. Evaluation of the safety profile of COVID-19 vaccines: A rapid review. BMC Med. 2021, 19, 173. [Google Scholar] [CrossRef]
- Dagan, N.; Barda, N.; Biron-Shental, T.; Makov-Assif, M.; Key, C.; Kohane, I.S.; Hernán, M.A.; Lipsitch, M.; Hernandez-Diaz, S.; Reis, B.Y.; et al. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy. Nat. Med. 2021, 27, 1693–1695. [Google Scholar] [CrossRef]
- Lv, M.; Luo, X.; Shen, Q.; Lei, R.; Liu, X.; Liu, E.; Li, Q.; Chen, Y. Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review. Vaccines 2021, 9, 1102. [Google Scholar] [CrossRef]
- Clinical Guidance on COVID-19 Vaccines for People with Metabolically Unstable Inborn Errors of Metabolism. Available online: http://www.bccdc.ca/Health-Info-Site/Documents/COVID19_vaccine/IEM_Clinical_Guidance.pdf (accessed on 22 August 2022).
- National Advisory Committee on Immunization. Recommendations on the Use of COVID-19 Vaccine(s). Available online: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html (accessed on 1 March 2021).
- Machingaidze, S.; Wiysonge, C.S. Understanding COVID-19 vaccine hesitancy. Nat. Med. 2021, 27, 1338–1339. [Google Scholar] [CrossRef]
- MacDonald, N.E. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [Google Scholar] [CrossRef]
- Dubé, E.; Laberge, C.; Guay, M.; Bramadat, P.; Roy, R.; Bettinger, J. Vaccine hesitancy: An overview. Hum. Vaccines Immunother. 2013, 9, 1763–1773. [Google Scholar] [CrossRef] [PubMed]
- Raccomandazioni ad Interim sui Gruppi Target Della Vaccinazione Anti SARS-CoV-2/COVID-19 Published on Gazzetta Ufficiale on 24 Marzo 2021. Available online: https://www.vaccinarsi.org/scienza-conoscenza/combattere-le-pandemie/covid-19-disposizioni-e-normative/raccomandazioni-ad-interim-sui-gruppi-target-della-vaccinazione-anti-sars-cov-2/covid-19 (accessed on 8 May 2021).
- Determina AIFA n. 73 del 31 Maggio 2021 “Estensione Indicazioni Terapeutiche di Specialità Medicinali”. Available online: https://www.aifa.gov.it/documents/20142/1289678/Det_73-2021_est_COMIRNATY.pdf (accessed on 31 May 2021).
- European Reference Network. Hereditary Metabolic Disorders and COVID-19 Vaccination. Available online: https://metab.ern-net.eu/wp-content/uploads/2020/07/COVID-19-Vaccine.pdf (accessed on 2 March 2021).
- Tummolo, A.; Paterno, G.; Dicintio, A.; Stefanizzi, P.; Melpignano, L.; Aricò, M. COVID-19 and Inherited Metabolic Disorders: One-Year Experience of a Referral Center. Children 2021, 8, 781. [Google Scholar] [CrossRef] [PubMed]
- COVID-19 Vaccination Program Operational Guidance. Available online: https://www.cdc.gov/vaccines/covid-19/covid19-vaccination-guidance.html (accessed on 6 February 2022).
- Li, J.; Hui, A.; Zhang, X.; Yang, Y.; Tang, R.; Ye, H.; Ji, R.; Lin, M.; Zhu, Z.; Türeci, Ö.; et al. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: A randomized, placebo-controlled, double-blind phase 1 study. Nat. Med. 2021, 27, 1062–1070. [Google Scholar] [CrossRef]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S. C4591001 Clinical Trial Group: Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef] [PubMed]
- Mulligan, M.J.; Lyke, K.E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Neuzil, K.; Raabe, V.; Bailey, R.; Swanson, K.A.; et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 2020, 586, 589–593. [Google Scholar] [CrossRef]
- Chu, L.; McPhee, R.; Huang, W.; Bennett, H.; Pajon, R.; Nestorova, B.; Leav, B.; on behalf of the mRNA-1273 Study Group. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine 2021, 39, 2791–2799. [Google Scholar] [CrossRef]
- European Centre for Disease Prevention and Control. Available online: https://vaccinetracker.ecdc.europa.eu/public/extensions/covid-19/vaccine-tracker.html#uptake-tab (accessed on 5 March 2022).
- Paneghetti, L.; Bellettato, C.M.; Sechi, A.; Stepien, K.M.; Scarpa, M. One year of COVID-19: Infection rates and symptoms in patients with inherited metabolic diseases followed by MetabERN. Orphanet J. Rare Dis. 2022, 17, 109. [Google Scholar] [CrossRef]
- Akın, E.Ö.; Eminoğlu, F.T.; Doğulu, N.; Yekeduz, M.K.; Öncül, U.; Akpınar, F.; Hayran, G. Unmet needs of children with inherited metabolic disorders in the COVID-19 pandemic. Turk. Arch. Pediatrics 2022, 57, 335–341. [Google Scholar] [CrossRef]
- Elmonem, M.A.; Belanger-Quintana, A.; Bordugo, A.; Boruah, R.; Cortès-Saladelafont, E.; Endrakanti, M.; Giraldo, P.; Grünert, S.C.; Gupta, N.; Kabra, M.; et al. The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspective. Mol. Genet. Metab. 2020, 131, 285–288. [Google Scholar] [CrossRef]
- Brunetti-Pierri, N.; Fecarotta, S.; Staiano, A.; Strisciuglio, P.; Parenti, G. Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: The experience of a metabolic unit in Italy. Genet. Med. 2020, 22, 1178–1180. [Google Scholar] [CrossRef]
- Tsai, R.; Hervey, J.; Hoffman, K.; Wood, J.; Johnson, J.; Deighton, D.; Clermont, D.; Loew, B.; Goldberg, S.L. COVID-19 Vaccine Hesitancy and Acceptance Among Individuals With Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey. JMIR Public Health Surveill. 2022, 8, e29872. [Google Scholar] [CrossRef] [PubMed]
- Gordon, J.K.; Showalter, K.; Wu, Y.; Kwakkenbos, L.; Carrier, M.E.; Henry, R.S.; Østbø, N.; Nordlund, J.; Bourgeault, A.; Cañedo-Ayala, M.; et al. Systemic sclerosis and COVID-19 vaccines: A SPIN Cohort study. Lancet Rheumatol. 2022, 4, e243–e246. [Google Scholar] [CrossRef]
- Haslak, F.; Gunalp, A.; Cebi, M.N.; Yildiz, M.; Adrovic, A.; Sahin, S.; Barut, K.; Kasapcopur, O. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study. Int. J. Rheum. Dis. 2022, 25, 353–363. [Google Scholar] [CrossRef] [PubMed]
- Davanzo, R.; Agosti, M.; Cetin, I.; Chiantera, A.; Corsello, G.; Ramenghi, L.A.; Staiano, A.; Tavio, M.; Villani, A.; Viora, E.; et al. Breastfeeding and COVID-19 vaccination: Position statement of the Italian scientific societies. Ital. J. Pediatrics 2021, 47, 45. [Google Scholar] [CrossRef]
- Cerutti, M.; De Lonlay, P.; Menni, F.; Parini, R.; Principi, N.; Esposito, S. Vaccination coverage of patients with inborn errors of metabolism and the attitudes of their parents towards vaccines. Vaccine 2015, 33, 6520–6524. [Google Scholar] [CrossRef]
- Klein, N.P.; Aukes, L.; Lee, J.; Fireman, B.; Shapira, S.K.; Slade, B.; Baxter, R.; Summar, M. Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics 2011, 127, e1139–e1146. [Google Scholar] [CrossRef] [PubMed]
- Hady-Cohen, R.; Dragoumi, P.; Barca, D.; Plecko, B.; Lerman-Sagie, T.; Zafeiriou, D. Safety and recommendations for vaccinations of children with inborn errors of metabolism. Eur. J. Paediatr. Neurol. 2021, 35, 93–99. [Google Scholar] [CrossRef]
- Morgan, T.M.; Schlegel, C.; Edwards, K.M.; Welch-Burke, T.; Zhu, Y.; Sparks, R.; Summar, M. Urea Cycle Disorders Consortium. Vaccines are not associated with metabolic events in children with urea cycle disorders. Pediatrics 2011, 127, e1147–e1153. [Google Scholar] [CrossRef]
- Klein, N.P. Children with inherited disorders tolerate routine vaccines as well as healthy children. Pediatrics 2011, 24, 14. [Google Scholar] [CrossRef] [Green Version]
Number | Percentage | |
---|---|---|
Total patients contacted | 192 | |
Total responder patients/available info | 174 | 90 |
Female gender | 85 | 47 |
Median age (min-max values) | 23.4 (12.1–61.7) | |
Diseases | ||
HPA/PKU | 107 | 61 |
OAD | 16 | 9 |
LSD | 7 | 4 |
UCD | 12 | 7 |
C-FAOD | 12 | 7 |
OARD | 10 | 6 |
CDG | 2 | 1 |
OTHER IMDs | 8 | 4 |
Number | Percentage | |
---|---|---|
Tot 174 | ||
Fully vaccinated (with second dose) | 151 | 87 |
Partially vaccinated (only one dose) | 163 | 94 |
Not vaccinated | 11 | 6 |
Previous COVD19 infection | 14 | 8 |
Subsequent COVID19 infection | 5 | 3 |
Tot 163 | ||
Type of vaccine | ||
Pfizer Biontech | 152 | 93 |
Moderna | 8 | 5 |
Astra-Zeneca | 1 | 0.6 |
Do not remember | 2 | 1 |
Vaccine administered at referral Hospital | 107 | 65 |
Adverse reaction to | ||
first dose | 99 | 60 |
second dose (tot 151) | 123 | 81 |
both doses (tot 151) | 52 | 34 |
Effects to First Dose | Effects to Second Dose, n (%) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Disease, n of Patients | Median Age | Not Vaccinated n (%) | Number/ Rate of Aes | Medical Referral, n (%) | Necessity of Treatment | Drug Used | Number/ Rate of AEs | Medical referral, n (%) | Necessity of Treatment, n (%) | Drug Used | Effect on Disease |
HPE/PKU 107 | 22 (12–51) | 8 (7) | 73 (73) | 3 (3) | 8 (8) | paracetamol, NSAIDs, corticosteroids | 89 (89) | 3 (3) | 21 (21) | paracetamol | 1 increase in Phe levels |
OAD 16 | 21 (13–39) | 0 | 3 (19) | 0 | 1 (6) | 5/13 (38) | 1 (8) | 2 (15) | paracetamol | none | |
UCD 12 | 20 (12–43) | 1 (8) | 2 (16) | 0 | 1 (9) | paracetamol | 4 (36) | 0 | 1 (9) | paracetamol | none |
C-FAOD 12 | 25 (12–42) | 0 | 6 (54) | 0 | paracetamol | 5 (45) | 0 | 1 (9) | paracetamol | none | |
OARD 10 | 21 (15–53) | 1(10) | 8 (88) | 0 | 3 (33) | paracetamol, NSAIDs | 8 (88) | 0 | 2 (22) | paracetamol | none |
LSD 7 | 20 (15–49) | 0 | 5 (71) | 0 | 0 | none | 4 (57) | 0 | 1 (7) | paracetamol | none |
OTHER 10 | 21 (12–61) | 1(10) | 3 (33) | 0 | 1 (11) | none | 8 (88) | 3 (33) | 4 (44) | paracetamol NSAIDs | none |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tummolo, A.; Dicintio, A.; Paterno, G.; Carella, R.; Melpignano, L.; De Giovanni, D. COVID-19 Vaccine in Inherited Metabolic Disorders Patients: A Cross-Sectional Study on Rate of Acceptance, Safety Profile and Effect on Disease. Int. J. Environ. Res. Public Health 2022, 19, 12227. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph191912227
Tummolo A, Dicintio A, Paterno G, Carella R, Melpignano L, De Giovanni D. COVID-19 Vaccine in Inherited Metabolic Disorders Patients: A Cross-Sectional Study on Rate of Acceptance, Safety Profile and Effect on Disease. International Journal of Environmental Research and Public Health. 2022; 19(19):12227. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph191912227
Chicago/Turabian StyleTummolo, Albina, Annamaria Dicintio, Giulia Paterno, Rosa Carella, Livio Melpignano, and Donatella De Giovanni. 2022. "COVID-19 Vaccine in Inherited Metabolic Disorders Patients: A Cross-Sectional Study on Rate of Acceptance, Safety Profile and Effect on Disease" International Journal of Environmental Research and Public Health 19, no. 19: 12227. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph191912227